I don't know how to treat amyloidosis

Research output: Contribution to journalComment/debate

21 Citations (Scopus)

Abstract

In this issue of Blood, Dietrich and colleagues report disappointing results with the use of melphalan parenterally with dexamethasone in patients with immunoglobulin light chain amyloidosis. The median survival of 61 patients was 17.5 months. The 3 months all cause mortality was 28%.

Original languageEnglish (US)
Pages (from-to)507-508
Number of pages2
JournalBlood
Volume116
Issue number4
DOIs
StatePublished - Jul 29 2010

Fingerprint

Immunoglobulin Light Chains
Melphalan
Amyloidosis
Dexamethasone
Blood
Survival
Mortality

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Immunology
  • Hematology

Cite this

I don't know how to treat amyloidosis. / Gertz, Morie.

In: Blood, Vol. 116, No. 4, 29.07.2010, p. 507-508.

Research output: Contribution to journalComment/debate

Gertz, Morie. / I don't know how to treat amyloidosis. In: Blood. 2010 ; Vol. 116, No. 4. pp. 507-508.
@article{1f45e2033c36448481ed3e301c61ae32,
title = "I don't know how to treat amyloidosis",
abstract = "In this issue of Blood, Dietrich and colleagues report disappointing results with the use of melphalan parenterally with dexamethasone in patients with immunoglobulin light chain amyloidosis. The median survival of 61 patients was 17.5 months. The 3 months all cause mortality was 28{\%}.",
author = "Morie Gertz",
year = "2010",
month = "7",
day = "29",
doi = "10.1182/blood-2010-04-279901",
language = "English (US)",
volume = "116",
pages = "507--508",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - I don't know how to treat amyloidosis

AU - Gertz, Morie

PY - 2010/7/29

Y1 - 2010/7/29

N2 - In this issue of Blood, Dietrich and colleagues report disappointing results with the use of melphalan parenterally with dexamethasone in patients with immunoglobulin light chain amyloidosis. The median survival of 61 patients was 17.5 months. The 3 months all cause mortality was 28%.

AB - In this issue of Blood, Dietrich and colleagues report disappointing results with the use of melphalan parenterally with dexamethasone in patients with immunoglobulin light chain amyloidosis. The median survival of 61 patients was 17.5 months. The 3 months all cause mortality was 28%.

UR - http://www.scopus.com/inward/record.url?scp=77956534627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956534627&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-04-279901

DO - 10.1182/blood-2010-04-279901

M3 - Comment/debate

C2 - 20671130

AN - SCOPUS:77956534627

VL - 116

SP - 507

EP - 508

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -